Jul 29 2010
T2 Biosystems, Inc., a company developing the first portable medical diagnostic products that combine nanotechnology and miniaturized magnetic resonance (MR) technology, today announced the company’s authorship of a chapter in the new book Point-of-Care Testing: Needs, Opportunity, and Innovation, 3rd Edition.
This book will be released during American Association of Clinical Chemistry (AACC) annual meeting, being held this week in Anaheim, CA.
T2 Biosystems authors, Tom Lowery, Rahul K Dhanda, and John McDonough, contributed Chapter 7 to the book, entitled, “Application of Magnetics in Point of Care Testing,” which reviews, amongst multiple other topics, T2’s proprietary technology, its applications and value to the healthcare system.
Point-of-care testing (POCT) is a key enabler of cost-savings and quality improvement in healthcare. Written by an internationally renowned collection of authors, this new book describes the developments that enable the delivery of diagnostic testing to decentralized settings. This is an essential book for all developers and manufacturers of POCT technology, those responsible for shaping healthcare policy, those who purchase or commission healthcare services, and those utilizing innovative diagnostic technologies.
T2 Biosystems is developing the next generation of medical diagnostic products through its proprietary technology, which combines nanotechnology and the miniaturization of proven MR technology. Building on dozens of prior published studies, this review demonstrates the potential of these new magnetic resonance-based diagnostics to offer improved speed, accuracy and efficiency as well as portability to a broader range of settings including doctor’s offices, homes and hospitals.
“Contributing to this book was a great opportunity and honor for T2 Biosystems to educate people about the power and potential of our technology,” said John McDonough, CEO of T2 Biosystems. “Furthermore, this important publication signals the reality of this technology to create a tremendous impact at all levels of healthcare as indicated by the advanced state of our assay and instrument development.
Source: http://www.t2biosystems.com/